Ultrasensitive Detection of Cancer with 3D Nano-engineered Microfluidic Chip

Ultrasensitive Detection of Cancer with 3D Nano-engineered Microfluidic Chip

University of Kansas researchers have developed a 3D printed nanochip capable of detecting circulating tumor exosomes providing an integrated analysis for total exosome levels, protein levels, and proteolytic activity. Overview: Early diagnosis of cancer is the most important factor in successful treatment however current methods of detection allow for only 20% of ovarian cancers to be detected at a stage early enough for treatment. The disclosed technology utilizes 3D printing of nanochips with the capability to detect exosomes in the blood and be a new method for the early diagnosis of many cancers.


Early detection of cancer is the most critical factor for successful treatment. There are very few current diagnostic tests approved by the FDA that have the capability to accurately detect early stages on the disease. This technology has the potential to detect cancer at such an early stage it could lessen the burden of cancer on patients and the economy.

Market Application

This technology is a 3D printed nanochip for exosome detection and analysis. Exosomes have been linked to ovarian, lung, breast, and other cancers and may be a source for biomarkers and early detection. The cancer diagnostic market is a nearly $150 billion industry only expect to grow. The exosome diagnostic sub-market is a newly emerging industry expected to exceed $2.3 billion in the next decade.

Additional Details

Owner: University of Kansas

IP Protection Status: Pending Patent